## Page 2 of 8

## **Todd Kremin**

From:

Robert Trumpy

Sent:

Thursday, July 27, 2006 4:55 PM

To:

'Matt Samuel'

Subject:

revised biosafe proj

Attachments: Retail proforma 07-27-06.xls

I looked at the expenses critically and increased several categories with the following logic. I now included those expenses that Biosafe would have incurred in running this level of revenue with the assumption that as of 8/1/06 expenses begin to increase with the new team gradually coming on board. The benefit of those added people will marginally be felt in 2006 and reach full value (ie. revenue increase) in 2007. The larger increase in expense for salaries/expenses in 2007 tracks with the increase in volume/revenue for 2007.

Call me if there are still concerns. As a reminder, the "going public" costs are not in any year per Andrews initial instructions.

Rob Trumpy, CPA SVP and CFO BioSafe Medical Technologies, Inc. 100 Field Drive, Suite 240 Lake Forest, IL 60045 Work:847-234-8111 Fax:847-234-8222 rtrumpy@ebiosafe.com

Retail Newco	Projected Income Statement	INTERNAL USE ONLY - Confidential
--------------	----------------------------	----------------------------------

					京教以事情報問題官由司徒信以下	新記載型では、新聞の問題のエート		一年の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の		and the state of the state of the state of
Product Revenue:	4				1					
Cholestestol Panel		↔	277,200	↔	450,450 \$	1,145,375	_			1,886,500
TSH		\$	255,906	<del>\$</del>	471,192 \$	1,218,600	•		· <del>69</del>	1,827,900
<b>∀</b> 5d		€.	357 000	<b>€</b> :	541.875 \$	1,083,750	\$ 1,78	1,785,000		1,912,500
2		÷	10.360	+ 4		691 530				932.400
religionii Alc		<del>)</del> (	000,01	<del>&gt;</del> €		001,000	) (i			2 781 500
Disease Management-Pharmacy		<del>50</del>	552,300	₽		1,288,700				200,107,2
Anemia Meter			4.185		209,250	781,200	8	837,000		627,750
						1 276 800	235	2.394.000	•	2.992.500
Rapid Allergy			•		I	20010111	0 0	74 350		2742500
New Development			1		1	,	λο, Ι	1,8/1/20		3,742,300
Internet			125,887		455,289	865,123	1,03	1,038,148	•	1,245,777
Revenue via Acquisition	ı			-		The state of the s			ľ	
Total Revenue			1,582,838		2,642,994	8,351,078	13,60	13,604,638	<del>-</del>	17,929,327
		u	R74 KE2	¥	967 206	3,123,325	\$ 4.82	4.825.089		6.386.897
Social Annual Manner		<b>.</b>	4,004	<b>&gt;</b> 6						
COGS VIA Acquismon		€	000	<b>→</b> ∈	077 700 e	880 088	1 08	1 D88 371 \$		1 434 346
Royalty to Biosate	ا %۵	A	170,021	A	1	_		1	•	F00 00F
Total Gross Margin % of Net Revenue			781,659 49%		1,474,348 56%	4,559,667 55%	89.' <i>,</i>	691,178 57%	<b>=</b>	10,108,084 56%
Selling, General and Administrative (non-public assumptions)	e (non-public	288	umptions)		52.860	167,022	27	272,093		358,587
Other Salaries	ì				150,000	570,000	65	650,000		730,000
Ottorio Sarvices from Biogafe					25,000					
menni Services non Diosale Doubli Hilling					50,000	120.000	12	120.000		180,000
			072		36 500	128 070	16	161,366		190,503
Payroll lax & Benefits			5,540		000'00	120,979	20	91,000		07,000
Professional					000'67	00000	~	000,0		000,10
General Insurance					10,00	30,000	4 (	40,000		45,000
Bad Debt @	1%		15,828		26,430	83,511	<u> </u>	136,046		179,293
Other Expenses					23,930	78,083	12	120,627		159,672
Advertising/Marketing	4%				26,430	334,043	54	544,186		717,173
Travel & Entertainment					10,000	35.000	4	40,000		75,000
-	ı		K2 025		435 150	1 621 637	2.16	2.165.318		2.722.708
Otal o, d & A			33,023			000 000 0	F F.2	K KOK RAD		7 385 376
EBITDA			7.28,534		1,038,186	7,950,050	40,0	200.5	-	2,000
% of Revenue			46%		39%	35%		4.1%		4. 7.4 0/
					000 066	265 000	25	315,000		370.000
Depleciation and Amortization	THE PARTY OF THE P	-	70000		040 400	2 673 030	521	5 210 BRO	7	7 015 376
EBIT			728,634		081,810	A, 01 3, 030	٥٫٨١	9000	•	
% of Revenue			46%		31%	32%		38%		%A5
:			000			E7 040	Ψ.	10.481		28 218
Interest Income			12,000		ı	21.6,10	-			2,01
Interest		***************************************	740 024		040 408	2 720 942	5 22	5 221 341		7 043 594
Pre Tax Profit (Loss)			740,034		0 8 1 80	4,130,346	3,40		•	2010101
Income Taxes			277.738		307,199	1,024,103	1,95	1,958,003	Z	2,641,348
Not Income	ì	***************************************	400 Cak		808 511 000	1 706 838	3.26	3 263 338	7	1 402.246
			000		330:>		1	2,20		

4/28/200811:46 AM

INTERNAL USE ONLY

Confidential

		ZOUS	KONO			
Assets				,		
	Cash		2,895,594	524,073	1,410,901	3,740,632
	Accounts Receivable (net of allowance)		377,571	1,193,011	1,943,520	2,561,332
	Inventories		100,000	200,000	250,000	2,400,000
	Prepaid Expenses		10,000	10,000	10,000	10,000
	retundable Deposits Total Current Assets	0	3,383,165	1,927,084	3,614,421	8,711,965
	Property, Equip & Cap Devl Costs, net	0	80,000	80,000	95,000	120,000
	Goodwill		4,000,000	4,000,000	4,000,000	4,000,000
	Product Licenses	0	4,800,000	5,560,000	6,280,000	6,960,000
	Total Assets	0	12,263,165	11,567,084	13,989,421	19,791,965
Liabilities	A/P Trade		121.166	348,247	517,246	677,543
	Payroll and Payroll Taxes		100,000	140,000	150,000	160,000
	Compliance Accrual		30,000	000'09	000'06	120,000
	Notes Payable - Current Total Current Liabilities	0	251,166	548,247	757,246	957,543
	Other Long Term Liabilities			(000 007 6)	(3.750.000)	72 850 0003
	Total Habilitae	0	264 466	(2.150,000)	(9,7,50,50)	(4 500 457)
	lotal Liabilities	>	201,102	(4,101,109)	(4,334,134)	(1,704,401)
Shareholders Equity	<b>×</b>					
	Common Stock	0	11,500,000	11,500,000	11,500,000	11,500,000
	Beg Retained Earnings	0	0	511,999	2,218,837	5,482,175
	Current Period Income(Loss)		511,999	1,706,838	3,263,338	4,402,246
	Ending Retained Earnings	0	511,999	2,218,837	5,482,175	9,884,422
	Total Stockholders Equity	0	12,011,999	13,718,837	16,982,175	21,384,422
Total Lishillfiae and	Total Lishillties and Stockholders Equity	C	12.263.165	11.567.084	13.989.421	19.791.965

Newco Retail Projected Statemer	ıt of Cash Flow	Newco Retail Projected Statement of Cash Flow INTERNAL USE ON⊾Y	Annual 2005	Annual 2006	Annual 2007	Amiual 2008	Annual 2009
Beg. Cash and Res	Beg. Cash and Reserve for Future Development	ment		0	2,895,594	524,073	1,410,901
Net income (loss)	:			511,999	1,706,838	3,263,338	4,402,246
Change in working capital (less cash): Current assets Current liabilities	apital (less cash):		0	(487,571) 251,166	(915,441) 297,080	(800,509) 208,999	(2,767,813) 200,297
Depreciation/Amortization Net PPE decrease (increa	Depreciation/Amortization Net PPE decrease (increase) including capitalized R & D	lized R & D	0	220,000 (5,100,000)	265,000 (1,025,000)	315,000 (1,050,000)	370,000 (1,075,000)
Goodwill purchase Issue of Note Payable for License Repayment of Note Payable	e for License Payable			(4,000,000) 2,500,000 (2,500,000)	(2,700,000)	(1,050,000)	2,000,000 (800,000)
Increase other long term liability Issuance of common stock, net of fees Ending Cash and Reserve for Future	Increase other long term liability Issuance of common stock, net of fees Ending Cash and Reserve for Future Development	opment	0	11,500,000 <b>2,895,594</b>	0 <b>524,073</b>	0 <b>1,410,90</b> 1	3,740,632
			0	0	0	0	0
Projected Long Ter	Projected Long Term Asset/Liability Work Schedule INTERNAL USE ONLY Confidential	Schedule Confidential	Annual 2005	Annual 2006	Annual 2007	Annual 2008	Annual 2009
	Fixed Assets	Beginning Balance Depreciation/Amort. Purchases/Cap R&D <b>Ending Balance</b>	0	0 (20,000) 100,000 <b>80,000</b>	80,000 (25,000) 25,000 80,000	80,000 (35,000) 50,000 95,000	95,000 (50,000) 75,000 120,000
	License Amort years 25	Beg. Balance Amortization New licenses Ending Balance	0	0 (200,000) 5,000,000 <b>4,800,000</b>	4,800,000 (240,000) 1,000,000 5,560,000	5,560,000 (280,000) 1,000,000 6,280,000	6,280,000 (320,000) 1,000,000 6,960,000
Projected Capitalization Table		INTERNAL USE ONLY Confidential	Annual 2005	Annual 2006	Annual 2007	Annual 2008	Annual 2009
	Beginning Shares Issued/Outstanding	ed/Outstanding		0	12,166,666	12,166,666	12,166,666
	Shares Issued During Period - # Ending Share Count	eriod = #	0	12,166,666	12,166,666	12,166,666	12,166,666
	alue a Dunir	sued Price Period - \$ \$ 1.00		2,500,000	12,000,000	12,000,000	12,000,000
Confidential	5,000,000 @ \$ 1,500,000 @ \$ 500,000 @ \$ 2,666,666 \$ Ending \$ Value at Issued Price	\$ 1.00 \$ - \$ 1.00 \$ 1.50 Led Price	5,000,000 INTERNAL USE ONLX,000,000 0 12,000,000	5,000,000 500,000 500,000 12,000,000	12,000,000	12,000,000	4/28/200811:46 AM <b>12,000,000</b>

			Send-in			20000000	Rapid tests	Total	
	Cholestestol	TSH	PSA	Hemoglobin C	Disease Mangt Ane Kits	Anemia Meter R	1	New Development	
1 ear	ranei		0001		1	÷ 00			
Stores Kite ner Storeklear	2,400	4,200	4,200	2002	80	90° 60			C
INIO POLICIO POR	14,400	12,600	16,800	800	000'09	300	1	ı	as
Thit Brice	19.25	20.31	21.25 \$					- 1	
Revenue 2005	\$ 277,200 \$		\$ 000,756	10,360 \$	552,300 \$	4,185 \$	••	\$ 1.45	1,456,951
	98,525	101,836	126,865 \$	4,523 \$	316,800 \$	825 \$			)7-
2008	асалыныналаккооонаяттүүнүүдү	unnumber de la companya de la compan	organisation de la descriptor de la company de la comp		THE RESIDENCE OF THE PROPERTY	And the state of t	ORBANISMOMORA OLOGOGRAPHA POLOGOGRAPHA POLOGOGRAPHA POLOGOGRAPA POLOGOGRAPA V POLOGOGR	erenstyrenjelik (A. 1920). Arkenstyl (A. 1930) erenstyrenskyrenskyrenskyrenskyrenskyrenskyrenskyrenskyrenskyre	CV-
Stores	3,900	5,800	5,100	1,200	1,900 25	2,500 6			-11
Kits per Store/year	23,400	23,200	25,500	6,000	47,500	15,000	1	ì	113
	\$ 19.25 \$	20.31			9.21 \$	13.95		1	
Revenue 2006	45	471,192 \$	1 1	\$ 002,77	ł	209,250 \$	· .	es e	2,187,705 See 148
2008	160,103	187,508 \$	192,563 \$	33,924 \$	250,800 \$	41,250 \$	,	1	
			0.00.00.00.00.00.00.00.00.00.00.00.00.0		мажения				
Stores	8,500	10,000	8,500	8,900	3,500	14,000	8,000	;	D
Kits per Store/year		<b>\$</b>	9000	6 6	40	4 58 000	8 64 nnn	۵ ,	00
	59,500	000'09	000,16	53,400	140,000	000,00			un
Unit Price		20.31 \$	21.25 \$	12.95 \$		13.95 \$	- 1	Į	
Revenue Revenue	1,145,375	ı	1 1		1,288,700 \$	- 1	1,276,800 \$	₽	7,485,955
COGS 2007	\$ 407,099 \$	484,935 \$	385,127 \$	301,924 \$	739,200 \$	154,000 \$	- 1	-	
									1-3
Stores	12,000	14,000	14,000	000'6	4,500	15,000	000,er	100,	6
Kits per Store/year	84,000	84,000	84,000	54,000	180,000	60,000	120,000	75,000	
	8					12 Of A	10 05	24 95	Fil
Unit Price	5 19.25 5	1 706 040 €	\$ 000 S87 1	\$ 008.90	1.656.900 \$	837.000 \$	į.	8	
	574,728	678,909 \$	634,326 \$	305,316 \$	1 1			8	4,617,459
					and the state of t	halanda da ayan da karan da karan da karan da ayan da da ayan	THE STREET STREET, STR	SCHOOL STREET,	4/
2003	14 000	15 000	15 000	12.000	10.000	15,000	15,000	15,000	30
Stores Kits ner Store/vear	7	900,00	9	9	30	60	10	10	/2
	000'86	000'06	000'06	72,000	300,000	45,000	150,000	150,000	008
Unit Price	\$ 19.25 \$	20.31 \$		1	1	- 1	i		
Revenue 2009	\$ 1,886,500 \$	1,827,900 \$	1,912,500 \$	932,400 \$	2,761,500 \$	627,750 \$	2,992,500 \$	3,742,500 \$ 16,68	16,683,55U 6 137 742
A POST A PROFESSION TO THE PROPERTY OF THE PROPERTY OF THE POST AND TH	670,516	727,403 \$	i.	407,088 \$	1,584,000 \$	1	8	<b>→</b>	_
	Cholesterol Panel	TSH	PSA	Hemoglobin A1c	Disease Management	Anemia R	Rapid Allergy De	New Development	ge 6
Cost of Goods Sold:								:	of
Kits (& outbound shipping)	2.00	3.95	1.20	1.49	1.95	2.50	6.79	5.00	8
Lab Processing (if any & net of non-compliance)	4.22	3.40	5.67	3.00 0.50	7.03	0.25	0.68	0.50	
Outsource Vendor Markup  Total Unit Cost	0.62 6.84	0.73 8.08	7.55	5.65	5.28	2.75	7.47	5.50	
Wholesale price	\$ 19.25 \$	20.31 \$	21.25 \$	12.95 \$	9.21	13.95 \$	19.95 \$	16.85	
Gross Margin %	64%	60%	64%	%99	43%	60%	0370	9	

Volume, Pricing and COGS

Newco Retail

## Newco Retail **Employee Listing**

Position	2005	2006	2007	2008
President		50.000		
		50,000	200,000	200,000
Chief Accountant			75,000	75,000
VP Sales			135,000	135,000
Brand Manager(s)		80,000	80,000	160,000
Sales Assistant		20,000	45,000	45,000
Admin			35,000	35,000
Total	-	150,000	570,000	650,000

2009
200,000
75,000
135,000
240,000
45,000
35,000
730,000